New Zealand King Salmon (ASX:NZK) - CEO and Managing Director, Grant Rosewarne
CEO and Managing Director, Grant Rosewarne
Source: NZK
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • New Zealand King Salmon Investments (NZK) raises NZ$50.3 million (A$45.75 million) through a rights offer to repay debt and fund operations for the next year
  • Shares will be issued at 14 cents each, with eligible shareholders taking up about 83.6 per cent of their entitlement under the offer
  • The company was originally seeking to raise NZ$60.1 million, so the NZ$9.8 million shortfall will be allocated to any retail shareholders who oversubscribed to the rights offer
  • The remainder of the shortfall will be taken up by the offer’s underwriter, Jarden
  • New Zealand Kind Salmon shares last traded at 26 cents each on Monday, May 9

New Zealand King Salmon Investments (NZK) has raised NZ$50.3 million (A$45.75 million) through a rights offer to repay debt and fund operations for the next year.

Shares will be issued at 14 cents each, with eligible shareholders taking up about 83.6 per cent of their entitlement under the offer.

The company was originally seeking to raise NZ$60.1 million. It will allocate the NZ$9.8 million shortfall to any retail shareholders who oversubscribed to the rights offer, with the remainder of the shortfall will be taken up by the offer’s underwriter, Jarden.

“NZ King Salmon is delighted with the level of take-up by its eligible shareholders in the rights offer,” Managing Director and CEO Grant Rosewarne said.

The company is one of the world’s largest producers of King Salmon, which it sells in a number of product formats.

The new shares are expected to begin trading on Friday.

New Zealand Kind Salmon shares last traded at 26 cents each on Monday, May 9.

NZK by the numbers
More From The Market Herald

" Talon Energy (ASX:TPD) progresses WA and Mongolia gas projects

Over the past three months, Talon Energy (ASX:TPD) has been focusing on its Walyering conventional gas…
Argenica Therapeutics (ASX:AGN) - CEO & Managing Director, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) completes phase one PK study

Argenica Therapeutics (ASX:AGN) has completed the final phase one pharmacokinetic (PK) study of ARG-007.
Beach Energy (ASX:BPT) - CEO, Morné Engelbrecht

" Beach Energy (ASX:BPT) appoints Morné Engelbrecht as CEO

Following an extensive international recruitment process, Beach Energy (ASX:BPT) has appointed Morné Engelbrecht as Chief Executive…
Titomic (ASX:TTT) - Managing Director, Herbert Koeck

" Titomic (ASX:TTT) on track to deliver world’s first mould coatings system

Additive manufacturing company Titomic (ASX:TTT) is on track to deliver the world's first automated cold spray…